Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (1141)	4/1/1998 11:45:00 AM
From: WeirdPro Randy	Read Replies (1) \| Respond to of 1359

<<Is there anyway to continue following these patients (long term) and assess valvular pathology even though it would no longer be blinded?>> These patients were on Redux as long as they could be, they stopped usage when the recall occurred. It is interesting to note that echo's were performed at an average time frame of 35 days following cessation of Redux, so we aren't going to be looking at questions of allowing their conditions to "regress" before the echo evaluation. However the IPIC Redux study due out by end of June is focusing on longer term (> 3 months) usage, and this will be blinded in the eyes of the evaluators......of course, the patients know who they are in this study.